STOCK-BASED COMPENSATION (Tables)
|
3 Months Ended |
12 Months Ended |
Mar. 31, 2026 |
Dec. 31, 2025 |
| Share-Based Payment Arrangement [Abstract] |
|
|
| Schedule of Stock-Based Compensation Expense |
Total stock-based compensation expense recognized in the Company’s consolidated statements of operations and comprehensive loss is classified as follows:
|
|
|
|
|
|
|
|
|
|
|
Three months ended March 31, |
|
|
|
2026 |
|
|
2025 |
|
Selling and marketing |
|
$ |
191,375 |
|
|
$ |
196,488 |
|
General and administrative |
|
|
11,186 |
|
|
|
101,517 |
|
Cost of revenue |
|
|
— |
|
|
|
105,734 |
|
Research and development |
|
|
— |
|
|
|
93,425 |
|
Total stock-based compensation expense |
|
$ |
202,561 |
|
|
$ |
497,164 |
|
|
Total stock-based compensation expense recognized in the Company’s consolidated statements of operations is classified as follows:
|
|
|
|
|
|
|
|
|
|
|
Year ended December 31, |
|
|
|
2025 |
|
|
2024 |
|
Cost of revenue |
|
$ |
105,734 |
|
|
$ |
466,658 |
|
Research and development |
|
|
93,425 |
|
|
|
476,666 |
|
Selling and marketing (1) |
|
|
360,639 |
|
|
|
(181,160 |
) |
General and administrative |
|
|
1,232,742 |
|
|
|
1,103,931 |
|
Total stock-based compensation expense |
|
$ |
1,792,540 |
|
|
$ |
1,866,095 |
|
_______________ (1)Amount presented for 2024 includes the reversal of stock compensation expense due to the departure of our Chief Marketing and Sales Officer in April 2024 and the resultant forfeiture of his unvested awards.
|
| Schedule of Restricted Stock Units |
|
The following table shows a summary of the Company's RSU activity for the year ended December 31, 2025:
|
|
|
|
|
|
|
|
|
|
|
RSUs |
|
|
|
Number of Shares |
|
|
Weighted Average Grant Date Fair Value |
|
Unvested at December 31, 2024 |
|
|
915 |
|
|
$ |
1,113.11 |
|
RSUs granted |
|
|
711,023 |
|
|
$ |
0.81 |
|
RSUs vested |
|
|
(711,559 |
) |
|
$ |
1.67 |
|
RSUs forfeited |
|
|
(379 |
) |
|
$ |
561.81 |
|
Unvested at December 31, 2025 |
|
|
— |
|
|
$ |
— |
|
The
|
| Summary of Stock Options Activity |
The following table shows a summary of the Company's stock option activity for the three months ended March 31, 2026:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of Stock Options Outstanding |
|
|
Weighted-Average Exercise Price |
|
|
Weighted-Average Remaining Contractual Life (Years) |
|
|
Aggregate Intrinsic Value |
|
Options outstanding at December 31, 2025 |
|
|
50,968 |
|
|
$ |
4.80 |
|
|
|
9.5 |
|
|
$ |
4,306.53 |
|
Options cancelled or forfeited |
|
|
(1,187 |
) |
|
$ |
113.77 |
|
|
|
|
|
|
|
Options outstanding at March 31, 2026 |
|
|
49,781 |
|
|
$ |
2.20 |
|
|
|
9.5 |
|
|
$ |
— |
|
Options exercisable at March 31, 2026 |
|
|
24,921 |
|
|
$ |
3.47 |
|
|
|
9.5 |
|
|
$ |
— |
|
Options vested and expected to vest at March 31, 2026 |
|
|
49,781 |
|
|
$ |
2.20 |
|
|
|
9.5 |
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of Stock Options Outstanding |
|
|
Weighted-Average Exercise Price |
|
|
Weighted-Average Remaining Contractual Life (Years) |
|
|
Aggregate Intrinsic Value |
|
Options outstanding at December 31, 2024 |
|
|
43,774 |
|
|
$ |
203.58 |
|
|
|
7.1 |
|
|
$ |
7,375.15 |
|
Options granted |
|
|
49,599 |
|
|
$ |
0.71 |
|
|
|
|
|
|
|
Options cancelled or forfeited |
|
|
(42,405 |
) |
|
$ |
204.38 |
|
|
|
|
|
|
|
Options outstanding at December 31, 2025 |
|
|
50,968 |
|
|
$ |
4.80 |
|
|
|
9.5 |
|
|
$ |
4,306.53 |
|
Options exercisable at December 31, 2025 |
|
|
13,696 |
|
|
$ |
15.15 |
|
|
|
8.9 |
|
|
$ |
1,076.57 |
|
Options vested and expected to vest at December 31, 2025 |
|
|
50,968 |
|
|
$ |
4.80 |
|
|
|
9.5 |
|
|
$ |
4,306.53 |
|
|
| Summary of Assumptions Utilized for Option Grants |
|
A summary of the weighted average assumptions the Company utilized for option grants during the years ended December 31, 2025 and 2024, respectively, are as follows:
|
|
|
|
|
|
|
Year ended December 31, |
|
|
2025 |
|
2024 |
Expected term (in years) |
|
5.2 |
|
4.0 |
Expected volatility |
|
134.0% |
|
47.8% - 55.0% |
Risk-free interest rate |
|
3.7% |
|
4.0% - 4.5% |
Expected dividend yield |
|
0.0% |
|
0.0% |
|
| Consultant Awards [Member] |
|
|
| Share-Based Payment Arrangement [Abstract] |
|
|
| Summary of Assumptions Utilized for Option Grants |
The Company determined the fair value using a Monte Carlo simulation based approach, a Level 3 valuation, with the following assumptions:
|
|
|
|
|
Three months ended March 31, |
|
|
2026 |
Stock Price |
$ |
$0.1773 - $0.2100 |
Expected term (in years) |
|
0.80 - 0.90 |
Expected volatility |
|
164.0% - 168.0% |
Risk-free interest rate |
|
3.4% - 3.7% |
Expected dividend yield |
|
0.0% |
|
|
| Lyocon Acquisition Awards [Member] |
|
|
| Share-Based Payment Arrangement [Abstract] |
|
|
| Summary of Assumptions Utilized for Option Grants |
The Company determined the fair value using a Monte Carlo simulation based approach, a Level 3 valuation, with the following assumptions:
|
|
|
|
|
Three months ended March 31, |
|
|
2026 |
Stock Price |
$ |
$0.1773 - $0.1837 |
Expected term (in years) |
|
0.80 - 1.00 |
Expected volatility |
|
168.0% - 175.0% |
Risk-free interest rate |
|
3.5% - 3.7% |
Expected dividend yield |
|
0.0% |
|
|